Biomarkers, Not DSM, Needed To Speed Dx, Drug Development For Brain Disorders
This article was originally published in The Gray Sheet
Diagnosing and treating brain disorders relies too much on subjective factors. But there are efforts brewing to turn that approach on its head, and move towards better biomarker-based diagnostics, says the Broad Institute’s Steven Hyman, former head of the National Institute of Mental Health.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.